Xinzhi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinzhi Li has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Bingshu E. Chen
Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada
2 shared publications - Guangdong Tong
Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China
2 shared publications - Limin Zhang
State Key Laboratory of Magnetic Resonance and Imaging, Innovation Academy of Precision Measurement Science and Technology, National Centre for Magnetic Resonance in Wuhan, Chinese Academy of Sciences (CAS), Wuhan, China
2 shared publications Na Zhou
Macau University of Science and Technology
2 shared publications- Wenjie Lai
School of Pharmacy, Faculty of Medicine & State Key Laboratory of Mechanism and Quality of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China
2 shared publications Xin Zhang
Macau University of Science and Technology
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (3) , e004884
Associations between accelerometer-measured physical activity, sedentary behaviour and pericardial adiposity: a prospective cohort study of UK Biobank participants
Introduction: Physical activity (PA) reduces the risk of atherosclerotic cardiovascular disease by limiting the overgrowth of fat tissue, particularly visceral adiposity. However, no large-scale studies have investigated the relationship between PA and pericardial adiposity. Methods: This study included 16 685 participants from the UK Biobank prospective cohort who underwent cardiac magnetic resonance assessment and had available PA data. PA was objectively measured using a wrist-worn triaxial accelerometer and categorised as light-intensity PA (LPA), moderate-intensity PA (MPA) and vigorous-intensity PA (VPA). Multivariable linear regression models were applied to estimate adjusted mean epicardial and pericardial adipose tissue (EPAT) areas across quartiles of total and intensity-specific PA, with linear trend analyses performed. Restricted cubic spline models were used to examine potential non-linear associations. The association between sedentary behaviour (SB) and EPAT area was also examined as a negative control. Results: Accelerometer-derived PA duration across all intensities was negatively correlated with EPAT area. Participants in the highest quartile (Q4) demonstrated smaller EPAT areas relative to those in the lowest quartile (Q1), with relative mean reductions of 21.29% for total PA, 11.24% for LPA, 18.28% for MPA and 19.10% for VPA (all p trend ≤0.001). Conversely, prolonged SB showed a positive correlation with EPAT area. Compared with those in Q1, individuals in Q4 in SB presented 15.90% greater relative mean EPAT area (p for trend <0.001). After adjustment for visceral adipose tissue volume, these associations were attenuated but remained significant. Stratified analyses confirmed that PA-EPAT association persisted among individuals with atherosclerotic cardiovascular disease, diabetes, hypertension or hyperlipidaemia. Mediation analysis showed VAT largely mediated the relationship between PA and EPAT area. Conclusions: PA reduces epicardial adiposity by limiting the overgrowth of EPAT area. These findings highlight the importance of PA as a preventive strategy for improving obesity-related health management worldwide.
- 1 July 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (3) , e004884
Open AccessAssociations between accelerometer-measured physical activity, sedentary behaviour and pericardial adiposity: a prospective cohort study of UK Biobank participants
Introduction: Physical activity (PA) reduces the risk of atherosclerotic cardiovascular disease by limiting the overgrowth of fat tissue, particularly visceral adiposity. However, no large-scale studies have investigated the relationship between PA and pericardial adiposity. Methods: This study included 16 685 participants from the UK Biobank prospective cohort who underwent cardiac magnetic resonance assessment and had available PA data. PA was objectively measured using a wrist-worn triaxial accelerometer and categorised as light-intensity PA (LPA), moderate-intensity PA (MPA) and vigorous-intensity PA (VPA). Multivariable linear regression models were applied to estimate adjusted mean epicardial and pericardial adipose tissue (EPAT) areas across quartiles of total and intensity-specific PA, with linear trend analyses performed. Restricted cubic spline models were used to examine potential non-linear associations. The association between sedentary behaviour (SB) and EPAT area was also examined as a negative control. Results: Accelerometer-derived PA duration across all intensities was negatively correlated with EPAT area. Participants in the highest quartile (Q4) demonstrated smaller EPAT areas relative to those in the lowest quartile (Q1), with relative mean reductions of 21.29% for total PA, 11.24% for LPA, 18.28% for MPA and 19.10% for VPA (all p trend ≤0.001). Conversely, prolonged SB showed a positive correlation with EPAT area. Compared with those in Q1, individuals in Q4 in SB presented 15.90% greater relative mean EPAT area (p for trend <0.001). After adjustment for visceral adipose tissue volume, these associations were attenuated but remained significant. Stratified analyses confirmed that PA-EPAT association persisted among individuals with atherosclerotic cardiovascular disease, diabetes, hypertension or hyperlipidaemia. Mediation analysis showed VAT largely mediated the relationship between PA and EPAT area. Conclusions: PA reduces epicardial adiposity by limiting the overgrowth of EPAT area. These findings highlight the importance of PA as a preventive strategy for improving obesity-related health management worldwide.
- Open Access
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1862457
A novel prenylflavonoid with efficacy in cancer therapy by targeting ceramide-orchestrated signaling
Background: Ceramide, acting as an important second messenger, plays a pivotal role in the induction of apoptosis in cancer cells. As one of the active prenylflavonoid ingredients in Epimedium , icariside I (GH01) has been shown to exhibit significant anticancer activity. However, the mechanism by which GH01 induces tumor cell apoptosis by targeting ceramide-orchestrated signaling remains unclear. Purpose: This study aimed to analyze the potential mechanism of GH01 for cancer therapy by generating ceramide formation in vivo and in vitro . Methods: A B16F10 melanoma-bearing mouse model was first established and treated with GH01 at different doses. Targeted quantification of ceramide was performed in vivo and in vitro using HPLC–QQQ-MS. A series of biological assays coupled with immunofluorescence staining and confocal microscope were utilized to analyze the apoptotic mechanism of tumor cells. Results: GH01 treatment markedly enhanced ceramide levels through the activation of ceramide de novo synthesis and sphingomyelin hydrolysis pathways coupled with the simultaneous suppression of sphingosine 1-phosphate generation. Consequently, high levels of ceramide promoted tumor cell apoptosis via both intrinsic and extrinsic apoptosis pathways. Notably, ceramide induced by GH01 interacted with mitochondria, thus releasing cytochrome c, which in turn activated caspase-9 and caspase-3, ultimately triggering cellular apoptosis. Additionally, the supplementation of inhibitors of caspase-3 and exogenous ceramide further confirmed the above apoptosis mechanism.
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1862457
Open AccessA novel prenylflavonoid with efficacy in cancer therapy by targeting ceramide-orchestrated signaling
Background: Ceramide, acting as an important second messenger, plays a pivotal role in the induction of apoptosis in cancer cells. As one of the active prenylflavonoid ingredients in Epimedium , icariside I (GH01) has been shown to exhibit significant anticancer activity. However, the mechanism by which GH01 induces tumor cell apoptosis by targeting ceramide-orchestrated signaling remains unclear. Purpose: This study aimed to analyze the potential mechanism of GH01 for cancer therapy by generating ceramide formation in vivo and in vitro . Methods: A B16F10 melanoma-bearing mouse model was first established and treated with GH01 at different doses. Targeted quantification of ceramide was performed in vivo and in vitro using HPLC–QQQ-MS. A series of biological assays coupled with immunofluorescence staining and confocal microscope were utilized to analyze the apoptotic mechanism of tumor cells. Results: GH01 treatment markedly enhanced ceramide levels through the activation of ceramide de novo synthesis and sphingomyelin hydrolysis pathways coupled with the simultaneous suppression of sphingosine 1-phosphate generation. Consequently, high levels of ceramide promoted tumor cell apoptosis via both intrinsic and extrinsic apoptosis pathways. Notably, ceramide induced by GH01 interacted with mitochondria, thus releasing cytochrome c, which in turn activated caspase-9 and caspase-3, ultimately triggering cellular apoptosis. Additionally, the supplementation of inhibitors of caspase-3 and exogenous ceramide further confirmed the above apoptosis mechanism.
- Open Access
- 27 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1775493
Immunopathological mechanisms and targeted intervention strategies for chronic chikungunya arthritis: from viral persistence to autoimmunity
Chronic chikungunya arthritis (CCA) is a major long-term sequela of Chikungunya virus (CHIKV) infection. Its pathogenesis involves persistent viral reservoirs in joint tissues, metabolic reprogramming of myeloid cells, dysregulated Treg/Th17 immunity, and autoimmune-like tissue injury. This review integrates recent advances in virology, immunometabolism, and clinical pathology to propose a four-stage pathological cascade: “viral persistence”, “myeloid metabolic dysregulation”, “Treg/Th17 imbalance”, and “autoimmunity-like injury”. Key cytokine networks and molecular interactions at each stage are summarized. Based on this model, we outline stage-specific therapeutic strategies, including antiviral agents targeting Mxra8 or nsP1 (Stage I), metabolic modulators such as HIF-1α inhibitors and IL-1β blockade (Stage II), immune-restorative therapies such as low-dose IL-2 and CTLA-4-Ig (Stage III), and anti-inflammatory biologics or DMARDs for RA-like pathology (Stage IV). This framework provides a mechanistic basis for precision intervention and supports the development of biomarkers and clinical trial designs for CCA.
- 27 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1775493
Open AccessImmunopathological mechanisms and targeted intervention strategies for chronic chikungunya arthritis: from viral persistence to autoimmunity
Chronic chikungunya arthritis (CCA) is a major long-term sequela of Chikungunya virus (CHIKV) infection. Its pathogenesis involves persistent viral reservoirs in joint tissues, metabolic reprogramming of myeloid cells, dysregulated Treg/Th17 immunity, and autoimmune-like tissue injury. This review integrates recent advances in virology, immunometabolism, and clinical pathology to propose a four-stage pathological cascade: “viral persistence”, “myeloid metabolic dysregulation”, “Treg/Th17 imbalance”, and “autoimmunity-like injury”. Key cytokine networks and molecular interactions at each stage are summarized. Based on this model, we outline stage-specific therapeutic strategies, including antiviral agents targeting Mxra8 or nsP1 (Stage I), metabolic modulators such as HIF-1α inhibitors and IL-1β blockade (Stage II), immune-restorative therapies such as low-dose IL-2 and CTLA-4-Ig (Stage III), and anti-inflammatory biologics or DMARDs for RA-like pathology (Stage IV). This framework provides a mechanistic basis for precision intervention and supports the development of biomarkers and clinical trial designs for CCA.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Tropical Medicine
- Vol. 2026 (1)
Development of an Immunofluorescence Lateral Flow Assay for Detecting Four Medically Important Snake Venoms in China
Snakebite envenomation requires rapid venom identification for effective treatment, a need unmet by current diagnostics in China. This study aimed to develop a rapid, multiplex immunofluorescence lateral flow assay for the simultaneous detection of four major venomous snakes: Deinagkistrodon acutus, Bungarus multicinctus, Naja atra , and Agkistrodon halys . Key findings demonstrated that the assays exhibited high sensitivity, with limits of detection (LODs) ranging from 0.6 to 1.2 ng/mL. Excellent specificity was confirmed, with no cross‐reactivity observed among the four venoms. In a rabbit envenomation model, the assays accurately quantified venom in various biological samples (venous serum, wound exudate) within 5 min. Receiver operating characteristic (ROC) curve analysis showed high diagnostic accuracy, with areas under the ROC curve (AUCs) ranging from 0.889 to 0.956. Assay accuracy was further verified by spike‐in recovery rates of 90.3%–109.6%. The results indicate that this novel multiplex immunoassay shows great potential as a point‐of‐care tool for the rapid and quantitative diagnosis of snakebites, showing great potential for preclinical application following further human sample validation.
- 1 January 2026
- Published by Wiley in Journal of Tropical Medicine
- Vol. 2026 (1)
Open AccessDevelopment of an Immunofluorescence Lateral Flow Assay for Detecting Four Medically Important Snake Venoms in China
Snakebite envenomation requires rapid venom identification for effective treatment, a need unmet by current diagnostics in China. This study aimed to develop a rapid, multiplex immunofluorescence lateral flow assay for the simultaneous detection of four major venomous snakes: Deinagkistrodon acutus, Bungarus multicinctus, Naja atra , and Agkistrodon halys . Key findings demonstrated that the assays exhibited high sensitivity, with limits of detection (LODs) ranging from 0.6 to 1.2 ng/mL. Excellent specificity was confirmed, with no cross‐reactivity observed among the four venoms. In a rabbit envenomation model, the assays accurately quantified venom in various biological samples (venous serum, wound exudate) within 5 min. Receiver operating characteristic (ROC) curve analysis showed high diagnostic accuracy, with areas under the ROC curve (AUCs) ranging from 0.889 to 0.956. Assay accuracy was further verified by spike‐in recovery rates of 90.3%–109.6%. The results indicate that this novel multiplex immunoassay shows great potential as a point‐of‐care tool for the rapid and quantitative diagnosis of snakebites, showing great potential for preclinical application following further human sample validation.
- Open Access
- 24 September 2025
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 20 (1) , 101645
Prostanoids in Liver Repair and Regeneration: Biosynthesis, Receptors, and Intercellular Communication
- 24 September 2025
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 20 (1) , 101645
Open AccessProstanoids in Liver Repair and Regeneration: Biosynthesis, Receptors, and Intercellular Communication
- Open Access
- 5 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1591394
Aqueous extracts of Portulaca oleracea L. alleviate atopic dermatitis by restoring skin barrier function
Background: Portulaca oleracea L. (PO) is an edible plant with a long medicinal history in traditional Chinese medicine for various inflammatory diseases, including skin disorders such as atopic dermatitis (AD). However, the anti-inflammatory effects and AD-alleviating mechanisms of PO remain unclear.Methods: PO aqueous extract was prepared from a water-soluble portion and then mixed with carbomer to obtain a hydrogel, which provided stable drug permeation and absorption in mouse skin. Amantadine acetate was identified as an abundant ingredient and further predicted to be a Janus kinase 1 (JAK1) inhibitor via molecular binding simulation. Mice with AD, established by repeated sensitization with 2,4-dinitrochlorobenzene (DNCB), were topically treated with PO hydrogel. Aurantiamide acetate was applied to HaCaT keratinocytes prior to inflammatory challenge in the presence or absence of JAK1-siRNA. Transcriptional and translational gene expressions associated with cutaneous inflammation or skin barriers were assessed by qPCR and Western blotting, respectively. Enzyme-linked immunosorbent assays were performed to detect immunoglobulin E and proinflammatory factors in skin tissue or serum. The phosphorylation of JAK1, signal transducer and activator of transcription (STAT)3, and STAT6 in keratinocytes and skin were analyzed by Western blotting.Results: In DNCB-sensitized mice, the PO hydrogel ameliorated skin lesions, lowered symptom scores, and reduced epidermal thickness by suppressing proinflammatory factor generation, oxidative stress, and the expression of CD4+. The PO hydrogel promoted the expression of caspase-14 and filaggrin, thereby helping restore skin barrier function in AD. The PO hydrogel and/or aurantiamide acetate inhibited the enzymatic activity of JAK1 and downstream (STAT)3/STAT6 signaling pathways in vitro and in vivo.Conclusion: PO significantly ameliorated skin lesions and restored epidermal barrier function in AD mice. This was achieved by suppressing JAK1 enzymatic activity and JAK1-mediated STAT signaling pathways.
- 5 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1591394
Open AccessAqueous extracts of Portulaca oleracea L. alleviate atopic dermatitis by restoring skin barrier function
Background: Portulaca oleracea L. (PO) is an edible plant with a long medicinal history in traditional Chinese medicine for various inflammatory diseases, including skin disorders such as atopic dermatitis (AD). However, the anti-inflammatory effects and AD-alleviating mechanisms of PO remain unclear.Methods: PO aqueous extract was prepared from a water-soluble portion and then mixed with carbomer to obtain a hydrogel, which provided stable drug permeation and absorption in mouse skin. Amantadine acetate was identified as an abundant ingredient and further predicted to be a Janus kinase 1 (JAK1) inhibitor via molecular binding simulation. Mice with AD, established by repeated sensitization with 2,4-dinitrochlorobenzene (DNCB), were topically treated with PO hydrogel. Aurantiamide acetate was applied to HaCaT keratinocytes prior to inflammatory challenge in the presence or absence of JAK1-siRNA. Transcriptional and translational gene expressions associated with cutaneous inflammation or skin barriers were assessed by qPCR and Western blotting, respectively. Enzyme-linked immunosorbent assays were performed to detect immunoglobulin E and proinflammatory factors in skin tissue or serum. The phosphorylation of JAK1, signal transducer and activator of transcription (STAT)3, and STAT6 in keratinocytes and skin were analyzed by Western blotting.Results: In DNCB-sensitized mice, the PO hydrogel ameliorated skin lesions, lowered symptom scores, and reduced epidermal thickness by suppressing proinflammatory factor generation, oxidative stress, and the expression of CD4+. The PO hydrogel promoted the expression of caspase-14 and filaggrin, thereby helping restore skin barrier function in AD. The PO hydrogel and/or aurantiamide acetate inhibited the enzymatic activity of JAK1 and downstream (STAT)3/STAT6 signaling pathways in vitro and in vivo.Conclusion: PO significantly ameliorated skin lesions and restored epidermal barrier function in AD mice. This was achieved by suppressing JAK1 enzymatic activity and JAK1-mediated STAT signaling pathways.
- Open Access
- 2 August 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1442086
Cross-talks between perivascular adipose tissue and neighbors: multifaceted nature of nereids
Perivascular adipose tissue (PVAT) is a unique fat depot surrounding blood vessels and plays a vital role in the progression of vascular remodeling and dysfunction. PVAT exhibits remarkable differences in structure, phenotype, origin, and secretome across anatomical locations. The proximity of PVAT to neighboring vascular beds favors a niche for bidirectional communication between adipocytes and vascular smooth muscle cells, endothelial cells, and immune cells. In this review, we update our understanding of PVAT’s regional differences and provide a comprehensive exploration of how these differences impact cross-talks between PVAT and the vascular wall. Different PVAT depots show different degrees of vasoprotective function and resilience to pathological changes such as obesity and vasculopathies, shaping multifaceted interactions between PVAT depots and adjacent vasculatures. The depot-specific resilience may lead to innovative strategies to manage cardiometabolic disorders.
- 2 August 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1442086
Open AccessCross-talks between perivascular adipose tissue and neighbors: multifaceted nature of nereids
Perivascular adipose tissue (PVAT) is a unique fat depot surrounding blood vessels and plays a vital role in the progression of vascular remodeling and dysfunction. PVAT exhibits remarkable differences in structure, phenotype, origin, and secretome across anatomical locations. The proximity of PVAT to neighboring vascular beds favors a niche for bidirectional communication between adipocytes and vascular smooth muscle cells, endothelial cells, and immune cells. In this review, we update our understanding of PVAT’s regional differences and provide a comprehensive exploration of how these differences impact cross-talks between PVAT and the vascular wall. Different PVAT depots show different degrees of vasoprotective function and resilience to pathological changes such as obesity and vasculopathies, shaping multifaceted interactions between PVAT depots and adjacent vasculatures. The depot-specific resilience may lead to innovative strategies to manage cardiometabolic disorders.
- Open Access
- 6 June 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (11) , e029512
Association Between Omega‐3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose–Response Meta‐Analysis of Randomized Controlled Trials
Background: Previous results provide supportive but not conclusive evidence for the use of omega‐3 fatty acids to reduce blood lipids and prevent events of atherosclerotic cardiovascular disease, but the strength and shape of dose–response relationships remain elusive. Methods and Results: This study included 90 randomized controlled trials, reported an overall sample size of 72 598 participants, and examined the association between omega‐3 fatty acid (docosahexaenoic acid, eicosapentaenoic acid, or both) intake and blood lipid changes. Random‐effects 1‐stage cubic spline regression models were used to study the mean dose–response association between daily omega‐3 fatty acid intake and changes in blood lipids. Nonlinear associations were found in general and in most subgroups, depicted as J‐shaped dose–response curves for low‐/high‐density lipoprotein cholesterol. However, we found evidence of an approximately linear dose–response relationship for triglyceride and non‐high‐density lipoprotein cholesterol among the general population and more evidently in populations with hyperlipidemia and overweight/obesity who were given medium to high doses (>2 g/d). Conclusions: This dose–response meta‐analysis demonstrates that combined intake of omega‐3 fatty acids near linearly lowers triglyceride and non‐high‐density lipoprotein cholesterol. Triglyceride‐lowering effects might provide supportive evidence for omega‐3 fatty acid intake to prevent cardiovascular events.
- 6 June 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (11) , e029512
Open AccessAssociation Between Omega‐3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose–Response Meta‐Analysis of Randomized Controlled Trials
Background: Previous results provide supportive but not conclusive evidence for the use of omega‐3 fatty acids to reduce blood lipids and prevent events of atherosclerotic cardiovascular disease, but the strength and shape of dose–response relationships remain elusive. Methods and Results: This study included 90 randomized controlled trials, reported an overall sample size of 72 598 participants, and examined the association between omega‐3 fatty acid (docosahexaenoic acid, eicosapentaenoic acid, or both) intake and blood lipid changes. Random‐effects 1‐stage cubic spline regression models were used to study the mean dose–response association between daily omega‐3 fatty acid intake and changes in blood lipids. Nonlinear associations were found in general and in most subgroups, depicted as J‐shaped dose–response curves for low‐/high‐density lipoprotein cholesterol. However, we found evidence of an approximately linear dose–response relationship for triglyceride and non‐high‐density lipoprotein cholesterol among the general population and more evidently in populations with hyperlipidemia and overweight/obesity who were given medium to high doses (>2 g/d). Conclusions: This dose–response meta‐analysis demonstrates that combined intake of omega‐3 fatty acids near linearly lowers triglyceride and non‐high‐density lipoprotein cholesterol. Triglyceride‐lowering effects might provide supportive evidence for omega‐3 fatty acid intake to prevent cardiovascular events.
- Open Access
- 7 June 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (11) , e025071
Omega‐3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose‐Response Meta‐Analysis of Randomized Controlled Trials
Background: Current evidence might support the use of omega‐3 fatty acids (preferably docosahexaenoic acid and eicosapentaenoic acid) for lowering blood pressure (BP), but the strength and shape of the dose‐response relationship remains unclear. Methods and Results: This study included randomized controlled trials published before May 7, 2021, that involved participants aged ≥18 years, and examined an association between omega‐3 fatty acids (docosahexaenoic acid, eicosapentaenoic acid, or both) and BP. A random‐effects 1‐stage cubic spline regression model was used to predict the average dose‐response association between daily omega‐3 fatty acid intake and changes in BP. We also conducted stratified analyses to examine differences by prespecified subgroups. Seventy‐one trials were included, involving 4973 individuals with a combined docosahexaenoic acid+eicosapentaenoic acid dose of 2.8 g/d (interquartile range, 1.3 g/d to 3.6 g/d). A nonlinear association was found overall or in most subgroups, depicted as J‐shaped dose‐response curves. The optimal intake in both systolic BP and diastolic BP reductions (mm Hg) were obtained by moderate doses between 2 g/d (systolic BP, −2.61 [95% CI, −3.57 to −1.65]; diastolic BP, −1.64 [95% CI, −2.29 to −0.99]) and 3 g/d (systolic BP, −2.61 [95% CI, −3.52 to −1.69]; diastolic BP, −1.80 [95% CI, −2.38 to −1.23]). Subgroup studies revealed stronger and approximately linear dose‐response relations among hypertensive, hyperlipidemic, and older populations. Conclusions: This dose‐response meta‐analysis demonstrates that the optimal combined intake of omega‐3 fatty acids for BP lowering is likely between 2 g/d and 3 g/d. Doses of omega‐3 fatty acid intake above the recommended 3 g/d may be associated with additional benefits in lowering BP among groups at high risk for cardiovascular diseases.
- 7 June 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (11) , e025071
Open AccessOmega‐3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose‐Response Meta‐Analysis of Randomized Controlled Trials
Background: Current evidence might support the use of omega‐3 fatty acids (preferably docosahexaenoic acid and eicosapentaenoic acid) for lowering blood pressure (BP), but the strength and shape of the dose‐response relationship remains unclear. Methods and Results: This study included randomized controlled trials published before May 7, 2021, that involved participants aged ≥18 years, and examined an association between omega‐3 fatty acids (docosahexaenoic acid, eicosapentaenoic acid, or both) and BP. A random‐effects 1‐stage cubic spline regression model was used to predict the average dose‐response association between daily omega‐3 fatty acid intake and changes in BP. We also conducted stratified analyses to examine differences by prespecified subgroups. Seventy‐one trials were included, involving 4973 individuals with a combined docosahexaenoic acid+eicosapentaenoic acid dose of 2.8 g/d (interquartile range, 1.3 g/d to 3.6 g/d). A nonlinear association was found overall or in most subgroups, depicted as J‐shaped dose‐response curves. The optimal intake in both systolic BP and diastolic BP reductions (mm Hg) were obtained by moderate doses between 2 g/d (systolic BP, −2.61 [95% CI, −3.57 to −1.65]; diastolic BP, −1.64 [95% CI, −2.29 to −0.99]) and 3 g/d (systolic BP, −2.61 [95% CI, −3.52 to −1.69]; diastolic BP, −1.80 [95% CI, −2.38 to −1.23]). Subgroup studies revealed stronger and approximately linear dose‐response relations among hypertensive, hyperlipidemic, and older populations. Conclusions: This dose‐response meta‐analysis demonstrates that the optimal combined intake of omega‐3 fatty acids for BP lowering is likely between 2 g/d and 3 g/d. Doses of omega‐3 fatty acid intake above the recommended 3 g/d may be associated with additional benefits in lowering BP among groups at high risk for cardiovascular diseases.
- Open Access
- 22 June 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Regional Heterogeneity of Perivascular Adipose Tissue: Morphology, Origin, and Secretome
Perivascular adipose tissue (PVAT) is a unique fat depot with local and systemic impacts. PVATs are anatomically, developmentally, and functionally different from classical adipose tissues and they are also different from each other. PVAT adipocytes originate from different progenitors and precursors. They can produce and secrete a wide range of autocrine and paracrine factors, many of which are vasoactive modulators. In the context of obesity-associated low-grade inflammation, these phenotypic and functional differences become more evident. In this review, we focus on the recent findings of PVAT’s heterogeneity by comparing commonly studied adipose tissues around the thoracic aorta (tPVAT), abdominal aorta (aPVAT), and mesenteric artery (mPVAT). Distinct origins and developmental trajectory of PVAT adipocyte potentially contribute to regional heterogeneity. Regional differences also exist in ways how PVAT communicates with its neighboring vasculature by producing specific adipokines, vascular tone regulators, and extracellular vesicles in a given microenvironment. These insights may inspire new therapeutic strategies targeting the PVAT.
- 22 June 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessRegional Heterogeneity of Perivascular Adipose Tissue: Morphology, Origin, and Secretome
Perivascular adipose tissue (PVAT) is a unique fat depot with local and systemic impacts. PVATs are anatomically, developmentally, and functionally different from classical adipose tissues and they are also different from each other. PVAT adipocytes originate from different progenitors and precursors. They can produce and secrete a wide range of autocrine and paracrine factors, many of which are vasoactive modulators. In the context of obesity-associated low-grade inflammation, these phenotypic and functional differences become more evident. In this review, we focus on the recent findings of PVAT’s heterogeneity by comparing commonly studied adipose tissues around the thoracic aorta (tPVAT), abdominal aorta (aPVAT), and mesenteric artery (mPVAT). Distinct origins and developmental trajectory of PVAT adipocyte potentially contribute to regional heterogeneity. Regional differences also exist in ways how PVAT communicates with its neighboring vasculature by producing specific adipokines, vascular tone regulators, and extracellular vesicles in a given microenvironment. These insights may inspire new therapeutic strategies targeting the PVAT.